How peptide purity is measured by HPLC — and what the number does not tell you

Almost every research peptide is sold with a purity figure attached, and almost nobody selling one explains how it was produced. The number is not a measurement of the vial in the sense most buyers assume. It is a ratio, taken from a chromatogram, at a wavelength somebody chose. Understanding how it is generated tells you what it can and cannot support.

What reversed-phase HPLC actually does

High-performance liquid chromatography separates a mixture by pushing it through a packed column under pressure. In the reversed-phase mode used for peptides, the stationary phase is non-polar — typically silica with C18 alkyl chains bonded to it — and the mobile phase is a polar water and acetonitrile gradient, usually with an acidic ion-pairing additive.

Components partition between the two phases according to how hydrophobic they are. More hydrophobic species spend longer associated with the stationary phase and emerge later. As the acetonitrile fraction rises through the gradient, progressively more hydrophobic material is released. A detector at the column outlet records what comes off and when.

The output is a chromatogram: detector response against time. Each peak is material eluting at a characteristic retention time. For a synthetic peptide the target compound is the dominant peak, and the smaller peaks around it are the synthesis-related species that survived purification.

Where the percentage comes from

Purity is calculated by area normalisation. The software integrates the area under every peak, sums them, and expresses the target peak as a percentage of that total. A reported 99% means the main peak accounts for 99% of the total integrated absorbance in the run.

Why the detection wavelength matters

Peptides are usually detected by ultraviolet absorbance, and the choice of wavelength changes the answer. Two are conventional:

• —214 nm — absorbance by the peptide bond itself. Every amide linkage in every peptide-like species in the sample contributes, which makes it the more honest choice for a purity assay.
• —280 nm — absorbance by aromatic side chains, principally tryptophan and tyrosine. Only species containing those residues appear at all.

The consequence is direct. A peptide with no aromatic residues can produce an impressive-looking chromatogram at 280 nm while impurities that also lack aromatics stay invisible. The same sample run at 214 nm will generally report a lower purity, because more of what is present is being counted. A certificate that does not state the detection wavelength has omitted something load-bearing.

One peak is not proof of one compound

Area normalisation assumes each peak corresponds to a single species. That assumption fails whenever two components co-elute — emerging at the same retention time and integrating as one peak. A co-eluting impurity is silently counted as target compound, and the reported purity is inflated by exactly that amount.

This is a known and studied problem in pharmaceutical peptide analysis, and it is why peak purity assessment exists as a discipline separate from simply running the assay [1]. Approaches include diode-array detection, which collects a full ultraviolet spectrum across the peak and checks whether the spectral shape stays constant from the leading edge to the tail, and orthogonal methods that separate on a different physical principle so species which co-elute in one system resolve in the other. Chromatography coupled directly to mass spectrometry attacks it from another direction, by asking what mass is present at each point across the peak [2].

A supplier quoting a purity figure without stating how peak homogeneity was established is quoting an upper bound, not a measurement.

The three things purity does not tell you

It does not confirm identity

A chromatogram shows a peak at a retention time. Retention time is characteristic of a compound under a given method, but it is not unique to it — other species can elute at the same point. A supplier running purity alone can accurately report 99% for material that is 99% one compound and 0% the compound named on the label. The figure would be correct and the vial would still be wrong.

It does not tell you how much peptide you have

Purity is a ratio; mass is a quantity. A vial containing 10 mg of powder at 99% purity does not contain 9.9 mg of peptide. Synthetic peptides are typically isolated as salts, and the counterion carried through from purification contributes to the weighed mass along with residual water. Determining how much peptide is actually present is a separate analysis, and the reporting of counterion content is an area where the field has only recently moved toward a consensus position [3].

It does not describe contamination that is not organic

An ultraviolet detector responds to species that absorb in the ultraviolet. Bacterial endotoxin, heavy metals and residual inorganic salts largely do not appear in the chromatogram at all. Each requires its own assay, and a release specification that stops at purity has not covered them.

What a useful purity statement contains

1. 01The figure itself, as a number rather than an adjective.
2. 02The method — reversed-phase HPLC, with the detection wavelength stated.
3. 03Whether peak homogeneity was assessed, and by what means.
4. 04A lot number and a date, so the figure refers to identifiable material.
5. 05An identity result alongside it, from an orthogonal method.

Every lot we release is specified at ≥99% purity by HPLC against an industry norm of 95%, with identity confirmed by an orthogonal method rather than inferred from retention time. The full release specification is published on each product page before purchase.

This article describes analytical methodology. It does not describe the use, effect or application of any compound. All products are supplied for laboratory and research purposes only.